Virtus LifeSci Biotech Products ETF
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index, which tracks the performance of biotechnology companies with at least one drug therapy approved by the FDA.
LifeSci Index Partners, LLC
LifeSci Index Partners, LLC is a New York-based index provider of healthcare-based stock market indices. The LifeSci team is comprised of investment professionals with experience in biotechnology equity research, in organic chemistry research in academia, and at pharmaceutical and biotechnology companies.
Matthew B. Brown
Executive Managing Director and Chief Operating Officer
Industry start date: 1999
Matthew Brown is executive managing director and chief operating officer at Virtus ETF Solutions, a Virtus affiliate since 2015, which operates a multi-manager ETF platform providing access to differentiated investment capabilities from select subadvisers. Mr. Brown is also a portfolio manager with Virtus ETF Advisers LLC.
Mr. Brown has been involved in the creation and administration of financial products over fifteen years. Prior to founding the predecessor firm to Virtus ETF Solutions in 2012, he served as director of operations for Factor Advisors. Previously, Mr. Brown co-founded ETP Resources, a consulting and data services business that continues to grow and serve the ETF industry. From 2008 to 2009, he headed U.S. operations and served as chief compliance officer for U.K.-based issuer SPA/London & Capital.
Earlier in his career, Mr. Brown was integral in the design, listing, and operational development of several innovative industry-first products, including the TDX family of funds for XShares and TD Ameritrade, the first ETFs to combine equity and fixed-income holdings in the same fund. He also gained experience trading and making markets in ETFs in the United States and the U.K. while working for LaBranche Structured Products. Mr. Brown began his career at the American Stock Exchange where he was first exposed to ETFs.
Mr. Brown earned a B.A. in economics from Boston College. He has been working in the investment industry since 1999.
ETFs distributed by ETF Distributors LLC, an affiliate of Virtus ETF Advisers LLC
Director of Capital Markets
Industry start date: 1988
Seth Kadushin is director of capital markets at Virtus ETF Solutions, a Virtus affiliate since 2015, which operates a multi-manager ETF platform providing access to differentiated investment capabilities from select subadvisers. In addition, Mr. Kadushin serves as portfolio manager for Virtus ETF Advisers LLC.
Prior to joining the predecessor firm to Virtus ETF Solutions in 2013, Mr. Kadushin worked at Euromoney Institutional Investor, Plc, where he developed large-scale investment management programs focusing on exchange-traded instruments and alternate investment strategies.
Previously, Mr. Kadushin was an options desk strategist at Wedbush Securities (2011-2012) and the head program trader at RBS Securities (2009-2011). Prior to 2009, Mr. Kadushin held senior-level positions at Lehman Brothers and Bear Sterns (JP Morgan), where he was a member of the cross asset policy committee charged with instituting the firm’s equity trading division guidelines.
Mr. Kadushin holds a B.B.A. in finance from Emory University. He earned an M.B.A. from Fordham University with a concentration in information systems. He has been working in the investment industry since 1988.
ETFs distributed by ETF Distributors LLC, an affiliate of Virtus ETF Advisers LLC
One of the most dynamic stock sectors, covering companies that design drugs, from entrepreneurial start-ups to global giants
Passively invests solely in firms that have completed multiple human clinical trials and received FDA approval to sell and market a drug
Equal stock weightings, rebalanced semi-annually, help ensure even relatively small firms with impressive performance can have a meaningful impact on returns
Positions & Distributions
|Security||% of Portfolio|
|SAREPTA THERAPEUTICS INC||
|BIOMARIN PHARMACEUTICAL INC||
|VANDA PHARMACEUTICALS INC||
|ENANTA PHARMACEUTICALS INC||
|NEUROCRINE BIOSCIENCES INC||
|LEXICON PHARMACEUTICALS INC||
|UNITED THERAPEUTICS CORP||
|Ex-Date||Record Date||Payable Date||Dividend Income||ST Capital Gains||LT Capital Gains||Distribution Total|
Performance & Risk
|1 Month||3 Month||YTD||1 Year||3 Years||5 Years||10 Years||Since Inception|
Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate, so your shares, when redeemed, may be worth more or less than their original cost.
Sales Charge and Expenses
Fees & Expenses
|Gross Expense Ratio||0.79|
|Number of Days Fund has Traded at a:|
|Period||Less than -2%||-1.51% to -2.00%||-1.01% to -1.50%||-0.51% to -1.00%||-0.01% to -0.50%||0.00% to 0.50%||0.51% to 1.00%||1.01% to 1.50%||1.51% to 2.00%||Greater than 2%|
|2014-Q4: 12/16/2014 through 12/31/2014||0||0||0||0||3||8||0||0||0||0|
|2015-Q1: 1/2/2015 through 3/31/2015||0||0||0||0||28||33||0||0||0||0|
|2015-Q2: 4/1/2015 through 6/30/2015||0||0||0||1||23||38||1||0||0||0|
|2015-Q3: 7/1/2015 through 9/30/2015||0||0||0||0||28||36||0||0||0||0|
|2015-Q4: 10/1/2015 through 12/31/2015||0||0||0||0||36||27||0||1||0||0|
|2016-Q1: 1/4/2016 through 3/31/2016||0||0||0||0||36||25||0||0||0||0|
|2016-Q2: 4/1/2016 through 6/30/2016||0||0||0||0||27||37||0||0||0||0|
|2016-Q3: 7/1/2016 through 9/30/2016||0||0||0||0||19||45||0||0||0||0|
|2016-Q4: 10/3/2016 through 12/30/2016||0||0||0||0||28||35||0||0||0||0|
|2017-Q1: 1/3/2017 through 3/31/2017||0||0||0||0||30||32||0||0||0||0|
|2017-Q2: 4/3/2017 through 6/30/2017||0||0||0||0||35||28||0||0||0||0|
|2017-Q3: 7/3/2017 through 9/29/2017||0||0||0||0||50||13||0||0||0||0|
|2017-Q4: 10/2/2017 through 12/29/2017||0||0||0||0||42||21||0||0||0||0|
|2018-Q1: 1/2/2018 through 3/29/2018||0||0||0||0||51||10||0||0||0||0|
Documents & Resources
Please consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. The prospectus contains this and other information about the Fund. Contact us at 1-888-383-0553 or visit www.virtus.com for a copy of the Fund's prospectus. Read the prospectus carefully before you invest or send money.
Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate so your shares, when redeemed, may be worth more or less than their original cost.
Closing Price: The Closing Price is the price of the last reported trade on the fund's primary exchange. If there has been no reported trade for a particular date, the Closing Price represents the 4PM Bid/Offer Midpoint.
4PM Bid/Offer Midpoint: The midpoint between the highest bid and the lowest offer on the listing exchange, as of the time that the Fund's NAV is calculated (usually 4:00pm Eastern Time).
Premium/Discount: The amount the Fund is trading above or below the reported NAV (based on 4PM Bid/Offer Midpoint).
The Fund is an exchange-traded fund (“ETF”). The “net asset value” (NAV) of the Fund is determined at the close of each business day, and represents the dollar value of one share of the Fund; it is calculated by taking the total assets of the Fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV of the Fund is not necessarily the same as its intraday trading value. Fund investors should not expect to buy or sell shares at NAV because shares of ETFs such as the Fund are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Thus, shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.
NAV returns are calculated using the Fund’s daily 4:00 p.m. NAV, and include the reinvestment of all dividends and other distributions (reinvested at the Fund's NAV on distribution ex-date). Market price returns are calculated using the 4:00 pm midpoint between the bid and offer, and include the reinvestment of all dividends and other distributions (reinvested at the 4:00pm bid/offer midpoint on distribution ex-date). Market price returns do not represent the return you would receive if you traded at other times.
SEC Yield is an annualized yield that is calculated by dividing the investment income earned by the Fund less expenses over the most recent 30 day period by the current NAV at the end of the 30 day period. The Subsidized Yield reflects fee waivers and/or expense reimbursements recorded by the Fund during the period. Without waivers and/or reimbursements, yields would be reduced. The Unsubsidized Yield does not adjust for any fee waivers and/ or expense reimbursements in effect. If the Fund does not incur any fee waivers and/or expense reimbursements during the period, the Subsidized Yield and Unsubsidized Yield will be identical.
Distribution Rate is the annual rate that an investor would receive if the most recent distribution remained the same going forward. The rate represents a single distribution from the Fund and does not represent total return of the Fund. The distribution rate is calculated by annualizing the most recent distribution and dividing it by the most recent NAV.
Returns for periods of less than one year are cumulative total returns.
Not insured by FDIC/NCUSIF or any federal government agency. No bank guarantee. Not a deposit. May lose value.
Distributed by ETF Distributors LLC